Dec 9, 2013
Selecta Biosciences Announces Successful Pre-clinical Study of...
SEL-201 demonstrated the ability to induce immune tolerance in a model of hemophilia A, showing that SEL-201 has the potential to serve as an adjunct therapy to avoid harmful neutralizing antibody response to Factor VIII treatment severely affecting hemophilia A patients.
Selecta Biosciences Distinguished as World Economic Forum Technology Pioneer 2014
Selecta Biosciences , innovator of immune targeting technology -platform%2Findex.cfm&esheet=50697499&newsitemid=20130827005481&lan=en-US&anchor=Synthetic+Vaccine+Particles+%28SVP%E2%84%A2%29&index=2&md5=867d510b0dab40a162b6fa6ec60341e6">Synthetic Vaccine Particles , has been awarded Technology Pioneer 2014 by the .
Mass High Tech
Selecta makes $900M deal with Sanofi
Selecta Biosciences Inc. in Watertown said Wednesday that it's made a deal with global drug developer Sanofi, worth up to $900 million, to discover immunotherapies for life-threatening food and other types of allergies.
Customer Interaction Solutions
Selecta Biosciences and Sanofi Sign Global Collaboration to Develop...
Selecta Biosciences, Inc. , a clinical-stage biopharmaceutical company developing a new class of synthetic vaccines and immunotherapies, today announced that it has entered into a strategic global collaboration with Sanofi to discover highly targeted, antigen-specific immunotherapies for life-threatening allergies.